Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Lixisenatide: A New Glucagon-Like Peptide-1 Agonist

 During 2010, 8.3% of the United States populations were living with diabetes [1]. Over 80% of those diagnosed with diabetes are classified as being overweight [2]. Excessive weight increases the extent of insulin resistance, thus, in overweight individuals; weight loss should be a priority therapeutic target in the management of diabetes [3]

Citation: Ho CW (2014) Lixisenatide: A New Glucagon-Like Peptide-1 Agonist. J Develop Drugs 3:e134. doi: 10.4172/2329-6631.1000e134

  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger
Top